Description
Adipotide 5mg – Prohibitin-Targeting Apoptotic Peptide for Adipose Tissue Research
Adipotide (also known as FTPP – Fat-Targeted Proapoptotic Peptide, Prohibitin-Targeting Peptide-1, or TP01) is a synthetic peptidomimetic agent designed to selectively target the vasculature of white adipose tissue (WAT) . Unlike conventional peptides that act through hormonal or enzymatic pathways, Adipotide functions through a ligand-directed mechanism that binds to specific receptors (prohibitin and annexin A2) on endothelial cells supplying white fat .
This unique mechanism positions Adipotide as a valuable research tool in the fields of obesity, metabolic dysfunction, angiogenesis, and even exploratory oncology research . The compound has been evaluated in primate research models, demonstrating rapid weight loss and improved insulin resistance in obese monkeys, establishing it as a prototype in a new class of candidate drugs .
Molecular Structure and Mechanism of Action
Structure: C₁₁₃H₂₁₀N₃₆O₃₀S₂
Molecular Weight: ~2617.23 g/mol
Purity: ≥98% (HPLC)
Adipotide is composed of two primary functional domains:
1. Targeting Domain: The cyclic peptide motif CKGGRAKDC is designed to bind selectively to the prohibitin (PHB) and annexin A2 (ANXA2) receptor complex. These proteins are believed to be specifically expressed on the surface of endothelial cells in blood vessels supplying white adipose tissue (WAT) . This binding confers tissue specificity, allowing Adipotide to distinguish between blood vessels in adipose tissue and those in other tissues .
2. Proapoptotic Domain: The GG-D(KLAKLAK)₂ sequence is an amphipathic peptidomimetic that disrupts mitochondrial membranes upon receptor-mediated cell internalization . Once bound and internalized, this domain triggers the collapse of mitochondrial membranes, leading to apoptosis of the targeted endothelial cells .
Research Applications
-
Adipose Tissue Vascular Targeting Research – Studies investigate the role of prohibitin and annexin A2 as targets for ligand-directed drug delivery to white adipose tissue vasculature .
-
Obesity and Metabolic Syndrome Research – Explores the potential of targeted endothelial apoptosis in reducing white adipose tissue mass and improving metabolic parameters such as insulin resistance .
-
Angiogenesis and Vascular Biology – Examines the selective induction of apoptosis in specific vascular beds and the subsequent tissue remodeling processes .
-
Prohibitin Receptor Research – Investigates the role of prohibitin (PHB) and annexin A2 (ANXA2) in fatty acid transport, vascular targeting, and cellular signaling pathways .
-
Exploratory Oncology Research – Adipotide’s ability to bind prohibitin, a protein overexpressed in certain cancer types (including breast, prostate, and ovarian malignancies), has prompted investigations into its potential relevance for studying tumor vasculature and cancer cell metabolism .
Technical Specifications
| Parameter | Specification |
|---|---|
| Molecular Formula | C₁₁₃H₂₁₀N₃₆O₃₀S₂ |
| Molecular Weight | ~2617.23 g/mol |
| Purity | ≥98% (HPLC) |
| Form | Lyophilized powder |
| Dosage | 5mg per vial |
| Sequence | H-Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys-Gly-Gly-D-type(Lys-Leu-Ala-Lys-Leu-Ala-Lys)₂ |
| Synonyms | FTPP, Prohibitin-targeting peptide 1, TP01 , Fat-Targeted Proapoptotic Peptide |
| Storage | -20°C; avoid freeze-thaw cycles |
Research Background
In a pivotal study published in Science Translational Medicine (2011), Adipotide was evaluated in obese Old World monkeys. After four weeks of treatment, obese monkeys lost on average 11% of their body weight, with MRI and DEXA confirming a 27% reduction in white adipose tissue . The study also demonstrated improved insulin resistance in the treated monkeys, while lean monkeys showed no weight loss, indicating the compound’s effect may be selective for obese subjects .
At experimentally determined optimal doses, monkeys from three different species displayed predictable and reversible changes in renal proximal tubule function . This primate research establishes Adipotide as a prototype in a new class of candidate drugs that may be useful for studying obesity in humans .
Important Safety Notice
⚠️ FOR RESEARCH PURPOSES ONLY
This product is strictly intended for in-vitro research and laboratory use only. It is not approved for human consumption, therapeutic use, or clinical applications by any regulatory authority (e.g., FDA, EMA, etc.). TargetMol and all suppliers state: “All products are for scientific research and drug registration only” .
Adipotide is not a medicinal product and has not been registered with the MHRA, EMA, or FDA.
This product is sold as a research chemical only. Not for human or veterinary therapeutic use.
There are no reviews yet.